Teva cut to Sell at UBS citing uncertainty over leadership transition (NYSE: TEVA) | Seeking Alpha
Teva Prepared to Fight Charges in Generics Probe If Talks Fail - Bloomberg
As Part of Cost-Cutting Plan, Teva Will Shut Down Twenty or More Manufacturing Sites | Ctech
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Teva Plummets on Downgrade Following $85M Opioid Settlement - TheStreet
Teva, AbbVie finalize $6.6 billion U.S. opioid settlements | Reuters
Teva jumps after Wall Street upgrades, analysts say stock 'too cheap to ignore'
Teva started at neutral at UBS on pricing and legal concerns (NYSE:TEVA) | Seeking Alpha
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
Suffering from missteps, drugmaker Teva struggles to heal own ills | The Times of Israel
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva boosted as FDA delays generic Copaxone - Globes
UBS raises Teva price target - Globes
Summer of Teva: The Mom Comfort Sandal
Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
Teva hires ex-Novartis executive to succeed CEO Schultz | Reuters
Teva Pharmaceuticals Archives - Drug Discovery and Development
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action - ADVFN
UBS cuts estimate of Teva's opioid liability - Globes
Teva Pharmaceuticals Could Face Billions in Damages From Opioid Lawsuits | Barron's
Teva says vaccine makers have not taken its offer to help produce jabs | Financial Times
Rebounding Teva is 'too cheap to ignore,' upbeat analysts say | Fierce Pharma
UBS raises Teva price target - Globes
Investors question green tint of Teva's $5bn sustainability bond | Financial Times
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Teva in Talks to Buy Allergan's Generic-Drug Unit - WSJ
